Stock Details
MRK is Merck & Co., Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 89.05$. Average daily volumn in 3 months 12.32M. Market cap 232.47B



Stock symbol : MRK. Exchange : NYSE. Currency : USD
Lastest price : 91.93$. Total volume : 8.07M. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Merck & Co., Inc. (MRK)
Last Price
91.93$
Change
-2.48
Volume
8.07M

Previous Close94.41
Open94.11
Day Range91.48-94.33
Bid91.74 x 800
Ask91.72 x 800
Volume8.07M
Average Volume12.32M
Market Cap232.47B
Beta0.37
52 Week Range70.89-95.72
Trailing P/E16.78
Foward P/E12.44
Dividend (Yield %)2.92%
Ex-Dividend Date2022-06-14



Financial Details


According to Merck & Co., Inc.'s financial reports the company's revenue in 2021 were 48.7B an increase( +17.07%) over the years 2020 revenue that were of 41.52B. In 2021 the company's total earnings were 13.05B while total earnings in 2020 were 7.07B( +85.71%).


Loading ...



Organization

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuti... cals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Market Cap:
232.47B
Revenue:
48.7B
Total Assets:
105.69B
Total Cash:
8.1B


News about "Merck & Co., Inc."

why-call-traders-should-consider-merck-stock-image

Why Call Traders Should Consider Merck Stock

Source from : SchaeffersResearch.com - 10 hours ago

Now looks like an ideal time initiate a long position on Merck stock Merck & Co., Inc.'s (NYSE:MRK) recent breakout above the $88 level took out both its 2021 and 2000 highs. Outperforming with 22.1% ...See details»


wedge-capital-management-l-l-p-nc-decreases-stock-holdings-in-merck-co-inc-nysemrk-image

Wedge Capital Management L L P NC Decreases Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Source from : Defense World - 2 days ago

Wedge Capital Management L L P NC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK โ€“ Get Rating) by 2.9% during the first quarter, according to the company in its most recent disclosure ...See details»


8-analysts-have-this-to-say-about-merck-co-image

8 Analysts Have This to Say About Merck & Co

Source from : Business Insider - 1 days ago

These 8 analysts have an average price target of $96.25 versus the current price of Merck & Co at $95.01, implying upside. Below is a summary of how these 8 analysts rated Merck & ...See details»


merckseagen-potential-deal-talks-pick-up-speed-wsj-image

Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ

Source from : Yahoo Finance - 4 days ago

Merck & Co Inc (NYSE: MRK) is pushing forward with a potential deal for Seagen Inc (NASDAQ: SGEN), Wall Street Journal reported, citing people familiar with the matter. The Journal mentioned that ...See details»


Merck & Co., Inc.: Merck Is Poised for Steady Growth Led by Immuno-Oncology Drug Keytruda and Vaccine Gardasil

Source from : YAHOO!Finance - 7 days ago

Find the latest Merck & Company, Inc. (MRK) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»


merck-said-to-move-forward-with-possible-seagen-deal-image

Merck said to move forward with possible Seagen deal

Source from : Seeking Alpha - 4 days ago

Merck & Co. (MRK) is said to be moving forward with a possible deal with cancer-focused biotech company Seagen Inc ...See details»


seagen-would-be-a-great-fit-for-merck-image

Seagen Would Be A Great Fit For Merck

Source from : Seeking Alpha - 2 days ago

While I would not be a buyer at current levels on a standalone basis, Seagen is a great company with a strong revenue base and great long-term growth prospects, and I think that Merck would be ...See details»


merck-presents-positive-results-from-phase-12-study-of-pneumococcal-conjugate-vaccine-image

Merck Presents Positive Results From Phase 1/2 Study Of Pneumococcal Conjugate Vaccine

Source from : Nasdaq - 7 days ago

Merck & Co., Inc. (MRK) said it has presented positive results from the phase 1/2 study, dubbed as V116-001, evaluating the safety, tolerability and immunogenicity of V116, the company's ...See details»


Merckโ€™s Interest in Seagen is Mounting; Now What?

Source from : Nasdaq - 4 days ago

J ust days ago, biotech company Seagen jumped after reports emerged that Merck was interested in buying the company. Now, the company gained another 3.5% in pre-market trading on ...See details»


merck-presents-positive-results-from-phase-12-study-evaluating-v116-the-companys-investigational-pneumococcal-conjugate-vaccine-for-adults-image

Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Companyโ€™s Investigational Pneumococcal Conjugate Vaccine for Adults

Source from : Joplin Globe - 7 days ago

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of positive results from the Phase 1/2 study, V116-001, evaluating the safety, tolerability and ...See details»


heres-why-a-menlo-park-drug-company-is-turning-from-a-rare-disease-to-focus-on-cancer-image

Here's why a Menlo Park drug company is turning from a rare disease to focus on cancer

Source from : The Business Journals - 4 days ago

Why rare disease drug developer #CorceptTherapeutics is making a major play against #cancer #ovariancancer #SiliconValley #biotech ...See details»


Merck considering purchase of cancer drug maker Seagen - WSJ

Source from : Reuters on MSN.com - 11 days ago

Drugmaker Merck & Co is considering buying cancer-focused biotech company Seagen Inc, the Wall Street Journal reported on Friday, citing people familiar with the matter.See details»


merck-innovation-fund-chief-screens-next-horizon-ventures-image

Merck innovation fund chief screens โ€˜next horizonโ€™ ventures

Source from : Crain's New York - 1 days ago

WHO HE IS Managing director, Merckโ€™s Global Health Innovation Fund. BORN Denton, Texas. RESIDES Bushwick. AGE 39. EDUCATION Bachelorโ€™s in biochemistry, University of Pennsylva ...See details»


merck-reportedly-eyeing-acquisition-of-seattle-biotech-giant-seagen-image

Merck reportedly eyeing acquisition of Seattle biotech giant Seagen

Source from : GeekWire - 10 days ago

Biopharma giant Merck is considering an acquisition of Seagen, the Seattle areaโ€™s biggest biotech company, according to a report in the Wall Street Journal Friday. The Journal reported that โ€œtalksโ€ฆ Re ...See details»